Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company committed to developing and commercializing novel treatments for rare and ultrarare genetic diseases, is proud to announce that Emil D. Kakkis, M.D., Ph.D., the company’s CEO and president, will be delivering a presentation at Bank of America’s 2023 Health Care Conference on Wednesday, May 10th at 9:20 a.m. PT. Join us at this highly anticipated event to learn more about how we are revolutionizing the way rare and ultrarare genetic diseases are treated.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx strives to revolutionize the way rare and ultrarare genetic diseases are treated. With an ever-growing portfolio of approved therapies and product candidates, the biopharmaceutical company is paving the way for patients to gain access to treatments for diseases with an unmet medical need. By targeting diseases with a clear biology for treatment, Ultragenyx is providing hope for those living with these conditions that have traditionally had no approved treatments.
Ultragenyx is a company spearheaded by a team of experts in the development and commercialization of treatments for rare diseases. Their mission is to get safe and effective therapies to patients as quickly and cost-effectively as possible. With this commitment, they strive to make a lasting impact on patients’ lives.